Digna Biotech, S.L. - Product Pipeline Review - H2 2011

Digna Biotech, S.L. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Digna Biotech, S.L. - Product Pipeline Review - H2 2011” provides data on the Digna Biotech, S.L.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Digna Biotech, S.L.’s corporate website, SEC filings, investor presentations and featured press releases, both from Digna Biotech, S.L. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Digna Biotech, S.L. - Brief Digna Biotech, S.L. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Digna Biotech, S.L. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Digna Biotech, S.L. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Digna Biotech, S.L.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Digna Biotech, S.L.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Digna Biotech, S.L. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Digna Biotech, S.L.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Digna Biotech, S.L..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Digna Biotech, S.L. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Digna Biotech, S.L.; Digna Biotech, S.L. - Key Therapeutics; Digna Biotech, S.L. - Pipeline Overview and Promising Molecules; Digna Biotech, S.L. - News; Digna Biotech, S.L. - Latest Updates; Digna Biotech, S.L. - Pipeline; Digna Biotech, S.L. - Discontinued/Dormant Projects SHOW LESS READ MORE >

List of Tables
List of Figures
Digna Biotech, S.L. Snapshot
Digna Biotech, S.L. Overview
Key Information
Key Facts
Digna Biotech, S.L. – Research and Development Overview
Key Therapeutic Areas
Digna Biotech, S.L. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Digna Biotech, S.L. – Pipeline Products Glance
Digna Biotech, S.L. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Digna Biotech, S.L.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Digna Biotech, S.L. – Drug Profiles
Extra Domain A
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa 5
Product Description
Mechanism of Action
R&D Progress
Interferon Alfa 5 + Intron A
Product Description
Mechanism of Action
R&D Progress
Methylthioadenosine
Product Description
Mechanism of Action
R&D Progress
NAFB002
Product Description
Mechanism of Action
R&D Progress
P17
Product Description
Mechanism of Action
R&D Progress
Vector gutless IL12
Product Description
Mechanism of Action
R&D Progress
Vector Semliky IL12
Product Description
Mechanism of Action
R&D Progress
Digna Biotech, S.L. – Pipeline Analysis
Digna Biotech, S.L. – Pipeline Products by Therapeutic Class
Digna Biotech, S.L. - Pipeline Products By Target
Digna Biotech, S.L. – Pipeline Products by Route of Administration
Digna Biotech, S.L. – Pipeline Products by Molecule Type
Digna Biotech, S.L. – Recent Pipeline Updates
Digna Biotech, S.L. – Locations And Subsidiaries
Head Office
Recent Developments
Feb 27, 2006: The University Of Navarra And Two Biotechnology Firms Ally Against Pulmonary Fibrosis
Oct 19, 2007: Digna Biotech Biotechnological Company And Isdin Laboratory Begin Phase II Of A Product For Scleroderma
Mar 02, 2006: Biotherapix And Digna Biotech Announce Collaboration For Developing The Novel Therapeutics
Mar 02, 2006: Biotherapix And Digna Biotech Announce Collaboration For Novel Therapeutics
Financial Deals Landscape
Digna Biotech, S.L., Deals Summary
Digna Biotech, S.L., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Hepacyl Therapeutics Secures $3.1 Million In Venture Financing
Digna Biotech Secures Venture Financing
Partnerships
Flamel Technologies Enters Into Co-Development Agreement With Digna Biotech
IDIBAPS, CIMA And Digna Biotech Enter Into Agreement With OWL Genomics
Biotherapix Enters Into Co-Development Agreement With Digna Biotech
Licensing Agreements
Biotecnol And Digna Biotech Enter Into Licensing Agreement With Genentech
Amsterdam Molecular Therapeutics Enters Into An Agreement With Digna Biotech
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Digna Biotech, S.L. – Pipeline by Therapy Area and Indication, H2 2011
Digna Biotech, S.L. – Pipeline by Stage of Development, H2 2011
Digna Biotech, S.L. – Monotherapy Products in Pipeline, H2 2011
Digna Biotech, S.L. – Combination Treatment Modalities in Pipeline, H2 2011
Digna Biotech, S.L. - Phase II, H2 2011
Digna Biotech, S.L. - Pipeline By Therapeutic Class, H2 2011
Digna Biotech, S.L. - Pipeline By Target, H2 2011
Digna Biotech, S.L. – Pipeline By Route of Administration, H2 2011
Digna Biotech, S.L. – Pipeline By Molecule Type, H2 2011
Digna Biotech, S.L. – Recent Pipeline Updates, H2 2011
Digna Biotech, S.L., Deals Summary
Hepacyl Therapeutics Secures $3.1 Million In Venture Financing
Digna Biotech Secures Venture Financing
Flamel Technologies Enters Into Co-Development Agreement With Digna Biotech
IDIBAPS, CIMA And Digna Biotech Enter Into Agreement With OWL Genomics
Biotherapix Enters Into Co-Development Agreement With Digna Biotech
Biotecnol And Digna Biotech Enter Into Licensing Agreement With Genentech
Amsterdam Molecular Therapeutics Enters Into An Agreement With Digna Biotech

List of Figures
Digna Biotech, S.L. – Pipeline by Therapy Area and Indication, H2 2011
Digna Biotech, S.L. – Pipeline by Stage of Development, H2 2011
Digna Biotech, S.L. – Monotherapy Products in Pipeline, H2 2011
Digna Biotech, S.L. – Combination Treatment Modalities in Pipeline, H2 2011
Digna Biotech, S.L. – Pipeline By Therapeutic Class, H2 2011
Digna Biotech, S.L. - Pipeline By Target, H2 2011
Digna Biotech, S.L. – Pipeline By Route of Administration, H2 2011
Digna Biotech, S.L. – Pipeline By Molecule Type, H2 2011